Estrella Immunopharma, Inc.ESLANASDAQ
LOADING
|||
Operating Income Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
13.40%
↑ 109% above average
Average (18q)
-141.09%
Historical baseline
Range
High:94.57%
Low:-1005.23%
Volatility
-779.5%
Relatively stable
| Period | Value |
|---|---|
| Q3 2025 | 13.40% |
| Q2 2025 | -163.46% |
| Q1 2025 | -100.37% |
| Q4 2024 | 68.90% |
| Q3 2024 | 14.50% |
| Q2 2024 | -741.15% |
| Q1 2024 | 54.00% |
| Q4 2023 | 45.44% |
| Q3 2023 | -1005.23% |
| Q2 2023 | -13.09% |
| Q1 2023 | 94.57% |
| Q4 2022 | -401.90% |
| Q3 2022 | 48.87% |
| Q2 2022 | -538.27% |
| Q1 2022 | -58.93% |
| Q4 2021 | 2.05% |
| Q3 2021 | 0.00% |
| Q2 2021 | 0.00% |
| Q1 2021 | 0.00% |